Secondary Circulating Prostate Cells Predict Biochemical Failure in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease

Table 4

(a) Association of CPC status and margin status with biochemical failure. (+) positive (−) negative, (b) Association of CPC status and capsule status with biochemical failure, (c) Association of CPC status and perineural infiltration with biochemical failure, (d) Association of CPC status and vascular infiltration with biochemical failure, (e) Association of CPC status and lymphatic infiltration with biochemical failure.

(a)

	Con biochemical failure	Total	RR
(a) Margin (+) CPC (+)	9	15	16.5
(b) Margin (+) CPC (−)	1	7	1.83
(c) Margin (−) CPC (+)	17	22	37.4
(d) Margin (−) CPC (−)	4	48	1.0

(b)

	Con biochemical failure	Total	RR
(a) Capsule (+) CPC (+)	13	22	12.6
(b) Capsule (+) CPC (−)	1	16	0.58
(c) Capsule (−) CPC (+)	12	15	35.0
(d) Capsule (−) CPC (−)	4	39	1.0

(c)

	Con biochemical failure	Total	RR
(a) PN (+) CPC (+)	20	25	100.0
(b) PN (+) CPC (−)	5	30	5.0
(c) PN (−) CPC (+)	5	11	20.9
(d) PN (−) CPC (−)	0	26	1.0

(d)

	Con biochemical failure	Total	RR
(a) V (+) CPC (+)	10	16	17.0
(b) V (+) CPC (−)	0	2	3.4
(c) V (−) CPC (+)	15	18	51.0
(d) V (−) CPC (−)	5	56	1.0

(e)

	Con biochemical failure	Total	RR
(a) L (+) CPC (+)	8	13	15.0
(b) L (+) CPC (−)	0	3	3.1
(c) L (−) CPC (+)	17	25	20.0
(d) L (−) CPC (−)	5	52	1.0

(f)

	CPC (+)	BF	CPC (−)	BF
Gleason 4	1	0	11	0
Gleason 5 + 6	31	16	23	2
Gleason 7	8	5	11	3
Gleason 8 + 9	8	4	1	0
Total